Journal of neurology, neurosurgery, and psychiatry
-
J. Neurol. Neurosurg. Psychiatr. · Mar 2020
Randomized Controlled Trial Multicenter StudyEffect of rovatirelin in patients with cerebellar ataxia: two randomised double-blind placebo-controlled phase 3 trials.
To investigate the efficacy of rovatirelin, a thyrotropin-releasing hormone analogue, for ataxias in patients with spinocerebellar degeneration (SCD). ⋯ Rovatirelin is a potentially effective treatment option for SCD.
-
J. Neurol. Neurosurg. Psychiatr. · Mar 2020
Multicenter StudyMinimal evidence of disease activity (MEDA) in relapsing-remitting multiple sclerosis.
This study aimed to define the minimal evidence of disease activity (MEDA) during treatment that can be tolerated without exposing patients with relapsing-remitting multiple sclerosis at risk of long-term disability. ⋯ Early marginal MRI activity of one to two new T2 lesions, in the absence of both relapses and CELs, is associated with a minor risk of future disability, thus representing a simple and valuable definition for MEDA.